Magnetic resonance-based imaging biopsy with signatures including topological Betti number features for prediction of primary brain metastatic sites
- PMID: 37603131
- DOI: 10.1007/s13246-023-01308-6
Magnetic resonance-based imaging biopsy with signatures including topological Betti number features for prediction of primary brain metastatic sites
Abstract
This study incorporated topology Betti number (BN) features into the prediction of primary sites of brain metastases and the construction of magnetic resonance-based imaging biopsy (MRB) models. The significant features of the MRB model were selected from those obtained from gray-scale and three-dimensional wavelet-filtered images, BN and inverted BN (iBN) maps, and clinical variables (age and gender). The primary sites were predicted as either lung cancer or other cancers using MRB models, which were built using seven machine learning methods with significant features chosen by three feature selection methods followed by a combination strategy. Our study dealt with a dataset with relatively smaller brain metastases, which included effective diameters greater than 2 mm, with metastases ranging from 2 to 9 mm accounting for 17% of the dataset. The MRB models were trained by T1-weighted contrast-enhanced images of 494 metastases chosen from 247 patients and applied to 115 metastases from 62 test patients. The most feasible model attained an area under the receiver operating characteristic curve (AUC) of 0.763 for the test patients when using a signature including features of BN and iBN maps, gray-scale and wavelet-filtered images, and clinical variables. The AUCs of the model were 0.744 for non-small cell lung cancer and 0.861 for small cell lung cancer. The results suggest that the BN signature boosted the performance of MRB for the identification of primary sites of brain metastases including small tumors.
Keywords: Betti Number; Brain metastasis; MRI; Machine learning; Radiomics; Topology.
© 2023. Australasian College of Physical Scientists and Engineers in Medicine.
References
-
- Achrol AS, Rennert RC, Anders C et al (2019) Brain metastases. Nat Rev Dis Prim 5(1):5. https://doi.org/10.1038/s41572-018-0055-y - DOI - PubMed
-
- Suh JH, Kotecha R, Chao ST et al (2020) Current approaches to the management of brain metastases. Clin Oncol 17(5):279–299. https://doi.org/10.1038/s41571-019-0320-3 - DOI
-
- Farris JC, Hughes RT, Razavian NB et al (2022) Brain metastasis incidence and patterns of presentation after definitive treatment of locally advanced non-small cell lung cancer: a potential argument for brain magnetic resonance imaging surveillance. Adv Radiat Oncol 8(3):101058. https://doi.org/10.1016/j.adro.2022.101058 - DOI - PMC
-
- Brain Tumor Registry of Japan (2005–2008) (2017) Neurol Med Chir (Tokyo) 57:9-102. https://doi.org/10.2176/nmc.sup.2017-0001
-
- Davis FG, Dolecek TA, McCarthy BJ et al (2012) Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neurooncology 14(9):1171–1177. https://doi.org/10.1093/neuonc/nos152 - DOI
MeSH terms
Grants and funding
LinkOut - more resources
Medical